Time to Reconsider MEDIBIO LTD ORD AUSTRALIA (OTCMKTS:MDBIF) After Less Short Sellers?

February 15, 2018 - By Nellie Frank

The stock of MEDIBIO LTD ORD AUSTRALIA (OTCMKTS:MDBIF) registered a decrease of 59.02% in short interest. MDBIF’s total short interest was 5,000 shares in February as published by FINRA. Its down 59.02% from 12,200 shares, reported previously. With 8,600 shares average volume, it will take short sellers 1 days to cover their MDBIF’s short positions.

It closed at $0.22 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medibio Limited engages in the research, development, and commercialization of medical diagnostic technology for mental health based on Heart Rate Variability technology in Australia. The company has market cap of $38.82 million. The firm also provides animal health, skincare, and agriculture products, which include AGRIPRO, REGEN, QCIDE, and TERMILONE. It currently has negative earnings. It serves clients in the fields of public service, military, aviation, and public health system, as well as health insurance providers.

More important recent Medibio Limited (OTCMKTS:MDBIF) news were published by: Tcbmag.com which released: “Mayo Clinic, Medibio Set First Clinical Trial Using Depression Diagnosis …” on January 02, 2018, also Bizjournals.com published article titled: “Medibio raises $14M for tech that helps diagnose mental-health disorders”, Bizjournals.com published: “Olympic medalist Michael Phelps joins health-tech company board” on June 05, 2017. More interesting news about Medibio Limited (OTCMKTS:MDBIF) was released by: Globenewswire.com and their article: “Medibio Signs Agreement with Striiv to Accelerate Commercialisation” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: